Atossa Therapeutics, Inc.

ATOS

US04962H5063

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 06/07/2024 am IST			5-day change	1st Jan Change
1.09 ^USD	-6.84%		-8.40%	+23.86%

02/07	Atossa Therapeutics Names Heather Rees CFO	MT
02/07	Atossa Therapeutics, Inc. Appoints Heather Rees as Chief Financial Officer	CI

Atossa Therapeutics, Inc.(NasdaqCM:ATOS) added to Russell 3000E Growth Index

July 01, 2024

Latest news about Atossa Therapeutics, Inc.

Atossa Therapeutics Names Heather Rees CFO	03/07	MT
Atossa Therapeutics, Inc. Appoints Heather Rees as Chief Financial Officer	03/07	CI
Atossa Therapeutics, Inc.(NasdaqCM:ATOS) added to Russell Small Cap Comp Value Index	01/07	CI
Atossa Therapeutics, Inc.(NasdaqCM:ATOS) added to Russell Small Cap Completeness Index	01/07	CI
Atossa Therapeutics, Inc.(NasdaqCM:ATOS) added to Russell 2000 Index	01/07	CI
Atossa Therapeutics, Inc.(NasdaqCM:ATOS) added to Russell 3000E Index	01/07	CI
Atossa Therapeutics, Inc.(NasdaqCM:ATOS) added to Russell 3000 Growth Index	01/07	CI
Atossa Therapeutics, Inc.(NasdaqCM:ATOS) added to Russell Microcap Index	01/07	CI
Atossa Therapeutics, Inc.(NasdaqCM:ATOS) added to Russell 2500 Value Index	01/07	CI
Atossa Therapeutics, Inc.(NasdaqCM:ATOS) added to Russell Microcap Growth Index	01/07	CI
Atossa Therapeutics, Inc.(NasdaqCM:ATOS) added to Russell 3000 Value Index	01/07	CI
Atossa Therapeutics, Inc.(NasdaqCM:ATOS) added to Russell 2000 Value Index	01/07	CI
Atossa Therapeutics, Inc.(NasdaqCM:ATOS) added to Russell 3000E Growth Index	01/07	CI
Atossa Therapeutics, Inc.(NasdaqCM:ATOS) added to Russell 2000 Growth Index	01/07	CI
Atossa Therapeutics, Inc.(NasdaqCM:ATOS) added to Russell 2000 Dynamic Index	01/07	CI
Atossa Therapeutics, Inc.(NasdaqCM:ATOS) added to Russell Microcap Value Index	01/07	CI
Atossa Therapeutics, Inc.(NasdaqCM:ATOS) added to Russell 2500 Growth Index	01/07	CI
Atossa Therapeutics, Inc.(NasdaqCM:ATOS) added to Russell Small Cap Comp Growth Index	01/07	CI
Atossa Therapeutics, Inc.(NasdaqCM:ATOS) added to Russell 2500 Index	01/07	CI
Atossa Therapeutics, Inc.(NasdaqCM:ATOS) added to Russell 3000 Index	01/07	CI
Atossa Therapeutics, Inc.(NasdaqCM:ATOS) added to Russell 3000E Value Index	01/07	CI
Atossa Therapeutics Doubles Z-Endoxifen Dose in Phase 2 Breast Cancer Study	28/06	MT
Atossa Therapeutics Announces Updated Protocol for Clinical Trial Evaluating (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast Cancer	28/06	CI
Atossa Therapeutics Set to Join Updated Russell 3000 Index	17/06	MT
Atossa Therapeutics, Inc. Announces Support of Clinical Study Testing New, Artificial Intelligence, Breast Cancer Risk Assessment Model	28/05	CI

Chart Atossa Therapeutics, Inc.

Duration

Period

More charts

Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is engaged in developing medicines in areas of significant unmet medical need in oncology with a focus on using (Z)-endoxifen to prevent and treat breast cancer. Its lead drug candidate under development is oral (Z)-endoxifen, which it is developing for both the prevention and treatment of breast cancer. (Z)-endoxifen is the potent Selective Estrogen Receptor Modulator for estrogen receptor inhibition and causes estrogen receptor degradation. In addition to its potent anti-estrogen effects, (Z)-endoxifen has been shown to target PKCB1, a known oncogenic protein, at clinically attainable blood concentrations. It is developing a form of (Z)-endoxifen which is administered orally for the potential treatment of breast cancer and reduction of breast density. It has completed four Phase I clinical studies and two Phase II clinical studies with its proprietary (Z)-endoxifen (including oral and topical formulations).

Sector

Biotechnology & Medical Research

Calendar

14/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.09 USD

Average target price

5.417 USD

Spread / Average Target

+396.94%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ATOSSA THERAPEUTICS, INC.	+23.86%	137M
MODERNA, INC.	+18.97%	45.34B
LONZA GROUP AG	+41.98%	40.42B
IQVIA HOLDINGS INC.	-10.06%	37.92B
ALNYLAM PHARMACEUTICALS, INC.	+31.15%	31.75B
CELLTRION, INC.	-7.79%	27.71B
ICON PUBLIC LIMITED COMPANY	+13.32%	26.52B
UNITED THERAPEUTICS CORPORATION	+43.05%	13.96B
MEDPACE HOLDINGS, INC.	+31.28%	12.44B
BIO-TECHNE CORPORATION	-7.41%	11.26B

Other Biotechnology & Medical Research